Home > News > Lumiphore and Echelon Biosciences Introduce Novel Cancer Assays
April 4th, 2006
Lumiphore and Echelon Biosciences Introduce Novel Cancer Assays
Abstract:
Lumiphore Inc. and Echelon Biosciences Inc. jointly announce the finalization of a license agreement that provides Echelon access to Lumiphore's proprietary lanthanide-complex technology for the development of TR-FRET assays and reagents for use in research and drug discovery in the field of phospholipid signaling and lipid-protein interactions.
Source:
prnewswire
Bookmark:
Lumiphore
Echelon Biosciences
Nanomedicine
Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013
Protein 'Passport' Helps Nanoparticles Get Past Immune System May 20th, 2013
New Nanopore Sensor Simplifies Analysis of Methylated DNA May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Announcements
JPK reports on single molecule research at IISER Pune in India using AFM and CellHesion techniques May 21st, 2013
Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013